BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells

BPR1K653 是一种新型 Aurora 激酶抑制剂,在 MDR1(P-gp170)介导的多药耐药癌细胞中表现出强大的抗增殖活性

阅读:8
作者:Chun Hei Antonio Cheung, Wen-Hsing Lin, John Tsu-An Hsu, Tzyh-Chyuan Hour, Teng-Kuang Yeh, Shengkai Ko, Tzu-Wen Lien, Mohane Selvaraj Coumar, Jin-Fen Liu, Wen-Yang Lai, Hui-Yi Shiao, Tian-Ren Lee, Hsing-Pang Hsieh, Jang-Yang Chang

Background

Over-expression of Aurora kinases promotes the tumorigenesis of cells. The

Significance

BPR1K653 is a novel potent anti-cancer compound, and its potency is not affected by the expression of the multiple drug resistant protein, MDR1, in cancer cells. Therefore, BPR1K653 is a promising anti-cancer compound that has potential for the management of various malignancies, particularly for patients with MDR1-related drug resistance after prolonged chemotherapeutic treatments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。